Brian Ramjattan

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

Barbara Romanowski, Tino F. Schwarz, Linda M. Ferguson et al. · Human Vaccines · 2011 · 194 citations · Full text

Veterinary Medicine, Immunology, Oncology +13

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination

Barbara Romanowski, Tino F. Schwarz, Linda M. Ferguson et al. · Human Vaccines & Immunotherapeutics · 2014 · 99 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

A Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/013) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain

Gordon Irving, Janos Pénzes, Brian Ramjattan et al. · Journal of Pain · 2011 · 66 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial

Agnihotram V. Ramanakumar, Paulo Naud, Cecília Roteli-Martins et al. · BMJ Open · 2016 · 44 citations · Full text

Medicine, Infectious Diseases, Oncology +17

<i>Post Hoc</i> Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA

Frank Struyf, Brigitte Colau, Cosette M. Wheeler et al. · Clinical and Vaccine Immunology · 2014 · 27 citations · Full text

Veterinary Medicine, Infectious Diseases, Oncology +17